Stocks in play: Marvel Biosciences Corp
Announces that it has successfully completed its 4-week good laboratory practice, FDA investigational new drug, dose-ranging dog and rat studies for its lead drug candidate MB-204 paving the way for Phase 1 human trials to begin. Marvel Biosciences Corp shares V.MRVL are trading up one cent at $0.08.
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
